A Phase I Study of the Angiopoietin-2 Inhibitor MEDI3617

David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I study of MEDI3617 for advanced solid tumors.

Clinical Pearls

David Hyman, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I study of MEDI3617 for advanced solid tumors.

  • This was a phase I study looking at MEDI3617 alone and in combination with carboplatin/paclitaxel, paclitaxel, or bevacizumab in patients with advanced solid tumors.
  • MEDI3617 is a selective angiopoietin-2 inhibitor and functions much like bevacizumab.
  • Several responses were seen in ovarian cancer when MEDI3617 was administered alone. At the highest dosage of MEDI3617, some patients experienced severe swelling that persisted after treatment was stopped.
  • Responses were also seen across other tumor types when MEDI3617 was used in combination with chemotherapies and bevacizumab.